Portfolio Lab

American Healthcare REIT, Inc.

  • Stock
  • Ticker AHR
  • NYSE

Real estate · REITs · USA

$57.54 −0.12%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of American Healthcare REIT, Inc. since 02/2024, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

AHRGlobal equities (VT)

$10,000 grew to $12,956. Global equities (VT): $10,273.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −14.0% in 10/2026, measured from the peak in 07/2026. It took 3 months to get back to the old peak.

1-year return
+19.3%
Return p.a. since 02/2024
+75.4%
Volatility p.a.
29.5%
Largest decline
−14.0%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue543541543573604651674742
Gross profit112108116118124139149177
Operating income9995103106112126137165
EBITDA146136145155167193209256
Net income-32-6.89.95611243131
Earnings per share-0.24-0.040.060.330.060.130.160.14
Balance sheet
Total assets4,4884,4644,5074,7705,4265,5995,7047,609
Liabilities2,1842,1592,0442,0502,0662,0771,9621,960
Equity2,2612,2622,4212,6783,3213,4823,6955,536
Cash7786133147115119157223
Cash flow
Operating cash flow6061711075581119167
Free cash flow6061711075581119167

Value it:DCF calculatorMultiples calculator

Annual returns

* partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
6 Nov 2026$0.14
7 Aug 2026$0.16
8 May 2026$0.13
27 Feb 2026$0.06
7 Nov 2025$0.33
8 Aug 2025$0.06
9 May 2025−$0.04
28 Feb 2025−$0.24
13 Nov 2024−$0.03
9 Aug 2024$0.01
14 May 2024−$0.04
22 Mar 2024−$0.41

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€12bn
Market cap in trading currency
$13.4bn
Enterprise value
$13.1bn
P/E
117.4
P/S
5.00
P/B
2.41
EV/Sales
4.92
EV/EBITDA
15.9
Earnings yield
0.9%
FCF yield
3.2%

Results (last four quarters)

Revenue
$2.67bn
Gross profit
$589m
EBITDA
$824m
Net income
$96.3m
Earnings per share
$0.49
Revenue per share
$11.51
Revenue growth
+29.5%
Earnings growth
−44.2%

Profitability

Gross margin
22.1%
Operating margin
20.2%
Net margin
3.6%
Return on equity
2.3%
Return on assets
1.3%

Balance sheet and cash flow

Cash
$223m
Cash per share
$0.96
Financial debt
–
Debt/equity %
–
Current ratio
–
Book value per share
$23.85
Operating cash flow
$422m
Free cash flow
$422m

Dividend

Dividend yield
1.74%
Dividend (12 months)
$1.00
Yield (12 months)
1.74%
Payout ratio
204%
Ex-dividend date
30 Sep 2026

Shares and trading

Shares outstanding
232m
Volume
2.59m
Avg. volume 3 months
3.09m
Relative volume
0.8

Price and technicals

Price
$57.54
1 day
−0.1%
52-week high
$59.39
52-week low
$45.69
Distance to 52-week high
−3.1%
Distance to 52-week low
+25.9%
Distance to 50-day line
+7.0%
Distance to 200-day line
+10.1%
RSI (14)
59
Volatility 1M
28.5%

Performance

1 week
−0.4%
1 month
+7.8%
3 months
+2.4%
6 months
+14.6%
YTD
+22.3%
1 year
+16.3%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has AHR performed since 02/2024?

$10,000 grew to $47,814 by 20 Nov 2026, which is +75.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is AHR?

Volatility was 29.5% per year, measured on monthly returns. The largest decline from a peak was −14.0%, with the low in 10/2026.

How does AHR compare with a broad equity ETF?

Over the same period Global equities (VT) returned +13.4% per year at 12.3% volatility, AHR returned +75.4% at 29.5%. The correlation of monthly returns was 0.30; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.